tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Leukemia D007938 74 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Hematoma D006406 5 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Lymphoproliferative Disorders D008232 7 associated lipids
Crohn Disease D003424 12 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Cholestasis D002779 23 associated lipids
Fibrosis D005355 23 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Thyroid Diseases D013959 8 associated lipids
Sinusitis D012852 9 associated lipids
Leukocytosis D007964 9 associated lipids
Glomerulonephritis D005921 35 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Hypoglycemia D007003 13 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Franke EK and Luban J Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. 1996 Virology pmid:8806510
Stremlau M et al. Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1. 2006 Virology pmid:16643975
Goldfeld AE et al. Cyclosporin A and FK506 block induction of the Epstein-Barr virus lytic cycle by anti-immunoglobulin. 1995 Virology pmid:7538254
Zhao W et al. Role of cellular FKBP52 protein in intracellular trafficking of recombinant adeno-associated virus 2 vectors. 2006 Virology pmid:16828834
Mistríková J et al. Increased neoplasm development due to immunosuppressive treatment with FK-506 in BALB/C mice persistently infected with the mouse herpesvirus (MHV-72). 1999 Viral Immunol. pmid:10532652
Gambarino S et al. Human Cytomegalovirus Impact on mir-146a Expression Levels in Kidney Transplant Patients. 2016 Viral Immunol. pmid:27077822
Shen ZY et al. Variations in the S and P regions of the hepatitis B virus genome under immunosuppression in vitro and in vivo. 2012 Viral Immunol. pmid:22946668
Mortola E et al. The use of two immunosuppressive drugs, cyclosporin A and tacrolimus, to inhibit virus replication and apoptosis in cells infected with feline immunodeficiency virus. 1998 Vet. Res. Commun. pmid:10066129
Tanaka Y et al. Suppression of feline coronavirus replication in vitro by cyclosporin A. 2012 Vet. Res. pmid:22546085
Kano R et al. Treatment of sterile panniculitis in a dog. 2004 Vet. Rec. pmid:15134169
Ofri R et al. Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: a comparison with cyclosporine A. 2009 Vet. J. pmid:17950639
Sestak K et al. Tacrolimus-FK506 induced immunosuppression in gnotobiotic piglets. 2000 Vet. Immunol. Immunopathol. pmid:11137126
Marsella R et al. Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study. 2004 Vet. Dermatol. pmid:15500481
Mauldin EA et al. Proliferative and necrotizing otitis externa in four cats. 2007 Vet. Dermatol. pmid:17845627
Banovic F et al. Tacrolimus therapy for dermal arteritis of the nasal philtrum refractory to surgery and anti-inflammatory therapy (doxycycline/niacinamide and topical fluocinolone) in a dog. 2018 Vet. Dermatol. pmid:28990239
Hilton H et al. Evaluation of four topical preparations for the treatment of cannon hyperkeratosis in a horse. 2008 Vet. Dermatol. pmid:19055613
Marsella R and Nicklin CF Investigation on the use of 0.3% tacrolimus lotion for canine atopic dermatitis: a pilot study. 2002 Vet. Dermatol. pmid:12174182
Rosenkrantz WS Pemphigus: current therapy. 2004 Vet. Dermatol. pmid:15030557
Olivry T et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. 2010 Vet. Dermatol. pmid:20456716
Kelley LS et al. Safety and tolerability of 0.1% tacrolimus solution applied to the external ear canals of atopic beagle dogs without otitis. 2010 Vet. Dermatol. pmid:20609208